Mental Health Staff's Perspectives on Tapering of Antipsychotic Medication: A Focus Group Study.
antipsychotic medication
mental health staff
qualitative study
schizophrenia
tapering
Journal
Qualitative health research
ISSN: 1049-7323
Titre abrégé: Qual Health Res
Pays: United States
ID NLM: 9202144
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
medline:
7
11
2023
pubmed:
15
9
2023
entrez:
15
9
2023
Statut:
ppublish
Résumé
Contemporary practices of long-term antipsychotic maintenance treatment for schizophrenia are being challenged, and clinicians must consider the possibilities of reducing long-term maintenance use. However, research indicates that people with schizophrenia receive little support from mental health staff to reduce antipsychotic medication. This article reports a study which aimed to investigate interdisciplinary mental health staff's accounts of tapering of antipsychotic medication and to explore different positions that mental health staff assign to themselves and others. Six focus groups were conducted with 39 mental health staff from outpatient clinics, inpatient units, forensic mental health units, and community mental health services. The data analysis combined analyses of the interactions during focus groups and the thematic content. Results were considered from a discourse analytic perspective considering the function and consequence of accounts applied by the mental health staff. The mental health staff accounted for their perspectives on tapering from the following three distinctive positions: 1) No, patients will eventually realize that they need the medication, 2) Yes, but tapering means running a big risk of relapse in symptoms, and 3) Yes, we need to welcome risks to support personal recovery. Our findings indicated that there was reluctance among interdisciplinary mental health staff to let service users make decisions and limited possibilities for people with schizophrenia to have their request for tapering of their antipsychotic medication met by mental health staff.
Identifiants
pubmed: 37710394
doi: 10.1177/10497323231195821
pmc: PMC10626979
doi:
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Langues
eng
Pagination
1165-1176Déclaration de conflit d'intérêts
Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Nat Rev Cardiol. 2016 Jan;13(1):36-47
pubmed: 26194552
Br J Psychiatry. 2012 Aug;201:83-4
pubmed: 22859572
Soc Sci Med. 2006 Jun;62(11):2861-73
pubmed: 16343722
Lancet. 2012 Jun 2;379(9831):2063-71
pubmed: 22560607
Psychiatr Serv. 2011 Dec;62(12):1470-6
pubmed: 22193795
Soc Sci Med. 2020 Jan 23;247:112811
pubmed: 32032839
J Clin Nurs. 2020 Aug;29(15-16):3012-3024
pubmed: 32353905
Nurs Inq. 1995 Sep;2(3):157-63
pubmed: 7664160
Issues Ment Health Nurs. 2016 Nov;37(11):820-828
pubmed: 27696916
Nat Rev Endocrinol. 2011 Oct 18;8(2):114-26
pubmed: 22009159
Int J Ment Health Nurs. 2019 Feb;28(1):318-329
pubmed: 30151987
Ment Retard. 1972 Feb;10(1):24-7
pubmed: 5059995
Schizophr Bull. 2021 Jul 8;47(4):1116-1129
pubmed: 33754644
Lancet Psychiatry. 2015 May;2(5):452-464
pubmed: 26360288
Soc Sci Med. 1997 Mar;44(5):681-92
pubmed: 9032835
Psychiatr Serv. 2010 Mar;61(3):293-9
pubmed: 20194407
BMJ. 2001 Mar 24;322(7288):724-7
pubmed: 11264215
PLoS One. 2019 Jun 20;14(6):e0218711
pubmed: 31220160
Psychol Med. 2012 Oct;42(10):2145-55
pubmed: 22340278
Qual Health Res. 2017 Mar;27(4):559-572
pubmed: 26984364
Soc Psychiatry Psychiatr Epidemiol. 2015 Aug;50(8):1297-308
pubmed: 25720809
Psychiatr Rehabil J. 2009 Summer;33(1):38-46
pubmed: 19592378
Arch Gen Psychiatry. 2012 Aug;69(8):776-86
pubmed: 22474070
Qual Health Res. 2007 Dec;17(10):1422-33
pubmed: 18000081
Br J Psychiatry. 2016 Nov;209(5):361-365
pubmed: 27802977
J Ment Health. 2018 Aug;27(4):322-328
pubmed: 28857636